Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMANSIAUX, Yohann
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorNOIZE, Pernelle
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.date.accessioned2020-05-15T10:05:11Z
dc.date.available2020-05-15T10:05:11Z
dc.date.issued2019
dc.identifier.issn1532-6535 (Electronic) 0009-9236 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7586
dc.description.abstractEnEye lens membrane cells require high cholesterol concentrations that might be counteracted by lipid-lowering drugs. Using a nationwide database, we conducted a nested case-control study to evaluate the risk of cataract development associated with the use of lipid-lowering drugs. Patients aged 45 years and over with first cataract surgery in 2014 (cases) and up to four controls matched on age, gender, diabetes, hypothyroidism, glucocorticoid use, cardiovascular risk and area of residence were included in the study. Among the 2,811 cases and 11,106 matched controls included, analyses showed a significantly increased risk of cataract surgery for a cumulative exposure to fibrates exceeding five years (adjusted odds ratio (aOR) 1.58, 95% confidence interval 1.17-2.15), unlike cumulative exposure to statins whatever the dose or duration of treatment (aORs from 1.00 to 1.08, none being significant). This study highlighted an increased risk of cataract surgery with prolonged use of fibrates, but not of statins. This article is protected by copyright. All rights reserved.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enUse of Lipid-Lowering Drugs and the Risk of Cataract: A Population-Based Nested Case-Control Study
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/cpt.1176en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29992538en_US
bordeaux.journalClinical Pharmacology and Therapeuticsen_US
bordeaux.page458-465en_US
bordeaux.volume105en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03212259
hal.version1
hal.date.transferred2021-04-29T12:29:23Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Pharmacology%20and%20Therapeutics&rft.date=2019&rft.volume=105&rft.issue=2&rft.spage=458-465&rft.epage=458-465&rft.eissn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.issn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.au=BEZIN,%20Julien&MANSIAUX,%20Yohann&NOIZE,%20Pernelle&SALVO,%20Francesco&BEGAUD,%20Bernard&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée